Form 4: Cumberland Pharmaceuticals Director Kenneth Krogulski Increases Stake Through 10b5-1 Trading Plan

Director Kenneth Krogulski of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Summary

• Kenneth Krogulski, a director at Cumberland Pharmaceuticals, has been consistently acquiring shares of the company's common stock.
• These purchases are being executed automatically under a pre-existing Rule 10b5-1 trading plan that was adopted on March 13, 2024.
• The transactions occurred on multiple dates between September 3, 2024, and September 30, 2024.
• The number of shares acquired per transaction ranged from 52 to 309.
• The prices paid per share varied from $1.22 to $1.38.
• Following these transactions, Krogulski directly owns 256,491 shares of Cumberland Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects routine transactions under a pre-arranged trading plan. The director's continued investment is a positive sign, but it's not necessarily indicative of a major shift in the company's prospects.

Positives

• The director's consistent purchases may signal confidence in the company's future prospects.
• The purchases are part of a pre-arranged 10b5-1 trading plan, which provides transparency and avoids concerns about insider trading.

Industry Context

Directors and officers often use 10b5-1 trading plans to buy or sell company stock over a period of time. This is a common practice to avoid accusations of insider trading, as the trades are pre-scheduled.

Stakeholder Impact

• The increased ownership by a director could be viewed positively by shareholders.

Key Dates